disease higher than stage IIB (i.e., parametrial tumor extension) are 53% and 75%, respectively, with MR imaging and 29% and 99%, respectively, with clinical assessment (5). For measuring tumor size, MR imaging was shown to be superior to CT or clinical examination (6) . Lymphadenopathy, although not included in the FIGO staging system, is the major factor driving treatment planning and is the best indicator of prognosis. For patients with clinically visible tumor, 18 F-FDG PET/CT is more sensitive than either CT or MR imaging in the evaluation of nodal involvement (Table 2 ) (7-9). Studies using histopathology as the gold standard have shown that 18 F-FDG PET and 18 F-FDG PET/CT have a fairly wide range of sensitivity (65%-86%) and high specificity (94%-97%) for lymph node detection in patients with advanced-stage cervical cancer without evidence of node metastasis on anatomic imaging (10, 11) . Currently, 18 F-FDG PET/CT is routinely used for radiation therapy planning. In addition, the extent of lymph node involvement on 18 F-FDG PET and PET/CT has been shown to be a strong predictor of disease-specific survival (Fig. 2) . The risk of disease recurrence increases incrementally on the basis of the most distant level of PET lymph node involvement, with a hazard ratio of 2.40 (95% confidence interval, 1.63-3.52) for pelvic, 5.88 (3.80-9.09) for paraaortic, and 30.27 (16.56-55.34 ) for supraclavicular involvement (12) . Radical trachelectomy and lymphadenectomy is a fertilitysparing treatment option for women with early-stage disease. Eligibility requirements include tumor smaller than 2 cm, distance from tumor margin to internal cervical os of more than 1 cm, and absence of lymph node metastases. MR imaging assesses the extent of local tumor with high accuracy (13) and is routinely used for patient selection. 18 F-FDG PET/CT is also used in many institutions to evaluate for lymphadenopathy. But because the test demonstrates low (32%) sensitivity in early-stage disease, its purpose is to identify ineligible candidates (14) . Surgical lymphadenectomy is performed on all patients undergoing fertility-sparing surgery, even in the absence of imaging evidence of lymph node metastases.
After treatment, disease will recur in approximately one third of patients treated for locally advanced cancer, and most of these recurrences will be within the first 2 y after initial therapy. Because 18 F-FDG PET results have been shown to be prognostic of patient survival, the NCCN guidelines state that a single PET/ CT examination can be performed 3-6 mo after chemoradiation (Table 1) . Patients with new, residual, or no disease on posttreatment imaging demonstrate 5-y survival rates of 0%, 46%, and 92%, respectively (15) . MR imaging is not routinely used in the posttreatment setting.
UTERINE ENDOMETRIAL CANCER
Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United States, with 52,630 new cases of uterine corpus cancer and 8,590 deaths predicted in 2014 (1) . Patients typically present with abnormal vaginal bleeding early in the course of disease, are screened with transvaginal pelvic ultrasound, and are diagnosed with endometrial biopsy. The FIGO system stages endometrial cancer surgically (Supplemental Table 1 ) (2), and imaging is not described. The NCCN guidelines for endometrial cancer work-up specify chest imaging and also mention MR imaging, CT, and 18 F-FDG PET as possible options to consider in patients suspected to have extrauterine disease (16) . A European imaging society recommends MR imaging for treatment planning (17) . The wide latitude provided in the consensus guidelines on pretreatment imaging for endometrial cancer reflects the variability in practice among institutions.
Hysterectomy and bilateral salpingo-oophorectomy is the first step in treatment of endometrial cancer patients presumed to be at stages I-III. Surgery can also include resection of the pelvic and paraaortic nodes to assess for lymphadenopathy, which is part of the staging criteria. Because lymphadenectomy can incur perioperative complications and long-term morbidity such as lymphedema, some centers have chosen to selectively perform the procedure only when the primary tumor demonstrates high-risk features. These are high-grade histology (grade 3 endometrioid, serous papillary, or clear cell adenocarcinomas), a tumor larger than 2 cm, deep (.50% thickness) myometrial invasion, or cervical stromal invasion (18) . If preoperative evaluation indicates likely stage IV cancer spread, curative surgical resection is not an option and the patient can be offered compassionate triage to chemotherapy and, if necessary, surgery for palliation.
Pretreatment imaging is obtained to plan surgery (Table 1 ). Because features of the primary tumor predict the likelihood of nodal metastases, sites with expertise in frozen section diagnosis often choose to forego imaging and make the decision to perform lymphadenectomy intraoperatively, based on the hysterectomy specimen. However, many institutions, especially in Western Europe and Asia, opt for preoperative MR imaging to determine whether lymphadenectomy will likely be required. In a multicenter audit of 775 cases over a 12-mo period in the United Kingdom, MR imaging demonstrated sensitivity and specificity of 77% and 88%, respectively, for detecting deep myometrial invasion; 42% and 97%, respectively, for detecting cervical stromal invasion; and 64% and 96%, respectively, for diagnosing pelvic lymphadenopathy (19) . PET/CT is more sensitive than CT or MR imaging for directly evaluating for nodal metastases (Table 2 ) and is useful for identifying tumorinvolved nodes for surgical resection (20) (21) (22) . Nevertheless, because the sensitivity of PET/CT is suboptimal in detecting small-volume disease, staging lymphadenectomy is still performed in patients without imaging evidence of extrauterine disease when the primary tumor demonstrates high-risk features.
Imaging is also used in the minority of patients for whom staging surgery is not indicated as the initial treatment choice. Between 3% and 5% of patients with high-grade tumor histology harbor disease beyond the uterus and abdominopelvic nodes, such as intrathoracic or bony metastases (stage IVB). Thus, in patients for whom biopsy demonstrates high-risk histology, PET/CT is used to identify unsuspected distant disease that would obviate the morbidity of a staging operation (23) . In patients with medical comorbidities that preclude surgery or those with tumor invading the bladder or bowel (stage IVA), MR imaging is obtained to delineate fields for radiotherapy, which constitutes an alternative initial therapy.
Most patients are cured after primary treatment, with 20%-25% developing recurrence, usually within the first 3 y. The majority of the recurrences are in patients with higher-risk tumors and with a 5% recurrence rate for those with stage I tumor. The most common sites for recurrent tumor are the lymph nodes, best assessed with PET/CT (Fig. 3) , and the vagina, best assessed on physical examination and biopsy. Whole-body PET or integrated PET/CT demonstrates 92%-93% sensitivity and 93%-100% specificity in detecting recurrent disease (24, 25) . Surveillance imaging in patients at high risk for recurrence has been suggested, as 20% present with clinically occult metastases (26) ; but this use remains controversial.
OVARIAN CANCER
Ovarian cancer is the leading cause of gynecologic cancer deaths in Western countries. In the United States, 21,980 new diagnoses and 14,270 deaths were projected for 2014. A classification system based on pathologic and genetic features defines 2 types of epithelial ovarian cancer (27) . Type I (25%) includes low-grade serous, lowgrade endometrioid, clear cell, and mucinous tumors; is usually confined to the ovary at diagnosis; and demonstrates an indolent clinical course. Type II (75%) includes high-grade serous, highgrade endometrioid, and undifferentiated carcinomas, typically present as stage III or IV disease and accounting for 90% of ovarian cancer deaths.
Ovarian cancer is diagnosed clinically on the basis of patient history, imaging, and serum tumor markers (CA-125) and confirmed histologically. Early diagnosis, in the phase when the tumor is ovary-confined and likely curable, remains a challenge. Screening trials using transvaginal pelvic ultrasound have proven ineffective, in part because of the low prevalence of tumor in the background of benign ovarian masses. In one trial of 25,327 women over age 50 y, 1.5% of ovarian cancer was noted among a 19.6% incidence of benign cysts (28) . In this context, MR imaging, demonstrating 81% sensitivity and 98% specificity for cancer detection, is used to characterize incidental ovarian masses and improve the positive predictive value of the imaging work-up (Table 1 ) (29) . In contrast, 18 F-FDG PET, demonstrating 58% sensitivity and 76% specificity, is not advised (30) .
The FIGO system stages ovarian cancer on the basis of findings at cytoreductive surgery and biopsy (Supplemental Table 1 ) (31). Prognosis is directly related to the successful resection of all visible tumor. Hence, standard treatment involves aggressive surgery followed by platinum-and taxane-based chemotherapy. Neoadjuvant chemotherapy followed by interval surgery is chosen for patients with medical comorbidities or with a tumor burden that is not amenable to complete resection.
Pretreatment imaging is used to define tumor extent and identify patients for whom primary surgery is unlikely to be successful. NCCN guidelines include abdominopelvic CT or MR imaging in this context (32) . A multicenter trial of 280 patients with advanced ovarian cancer reported equal accuracy for CT and MR imaging (area under the curve [AUC], 0.96 for both) for diagnosis of intraperitoneal tumor implants (33) . Because CT is more widely available, is better tolerated, and yields higher-resolution anatomic information, it is the chosen modality at most institutions. Although fusion PET/CT shows higher staging accuracy, mostly by identifying extraabdominopelvic disease, it has not been widely adopted, as evidence that this capability alters treatment is lacking. Although most patients will respond to primary therapy, 60%-70% will eventually relapse, and almost all of them will die from their disease.
Surveillance involves physical examination and serial serum CA-125 measurements in most patients. Imaging is reserved for those in whom recurrence is suspected. In this setting, PET/CT (AUC, 0.96) demonstrates better diagnostic performance than CT (AUC, 0.88) or MR imaging (AUC, 0.80) ( Table 1 ) (34) and better interpreter agreement than CT (35) .
MR IMAGING TECHNOLOGIES IN DEVELOPMENT
Several newer MR imaging techniques show potential to add to the capability of MR imaging in lesion detection and characterization. These include dynamic contrast-enhanced (DCE) imaging, diffusion-weighted imaging (DWI), intrinsic susceptibilityweighted or blood oxygen level-dependent imaging, and proton spectroscopy. The latter two are primarily investigational tools. In contrast, standard protocols for evaluating the female pelvis routinely include DCE MR imaging and DWI. Research has focused on developing these methods as imaging biomarkers.
DCE MR imaging measures the kinetic profile of an intravenously injected bolus of gadolinium contrast as it passes from the neovascularity within the tumor into the extracellular space, thereby modeling tumor perfusion. Quantitative results are obtained by directly measuring descriptive data, such as initial area under the gadolinium curve, or by applying a pharmacokinetic mathematic model (36) to generate physiologic parameters, such as the volume of the extracellular, extravascular leakage space.
DCE MR imaging is routinely performed qualitatively in endometrial cancer patients to diagnose deep myometrial invasion, where it demonstrates 77%-88% sensitivity and 61%-100% specificity (37, 38) . Quantitative DCE MR imaging parameters have been reported to predict the outcome of cervical cancer radiotherapy (39) and to aid in discriminating benign from malignant adnexal masses (40) . These results, if verified by independent investigators, would represent useful tools for development of adaptive therapy and noninvasive diagnosis, respectively. DWI measures the Brownian motion of extracellular water and thereby approximates tissue cellularity and fluid viscosity. A series of pulse sequences incrementally weighted to diffusion is acquired by successively altering the amplitude, duration, and spacing of magnetic field gradients. These gradients spoil the signal from moving protons, accentuating the signal from protons slowed by cell packing or high fluid viscosity. The apparent diffusion coefficient (ADC) is a quantitative parameter derived from the exponential attenuation of signal between at least 2 acquisitions with different amounts of diffusion weighting. Restricted diffusion is depicted as high signal on the index diffusion-weighted images and low signal in the corresponding ADC maps. Thus, DWI provides concurrent lesion detection over a large field of view and quantitative tissue characterization.
Malignant tissue demonstrates restricted diffusion, that is, low ADC values, which normalize after therapy. As the increase in ADC values precedes decreased morphologic size, ADC values measured early during the course of therapy have been studied as a possible predictive biomarker. In a series of 111 patients with endometrial cancer, a multivariate analysis showed that the pretreatment minimal ADC of the primary tumor was an independent prognostic factor of disease recurrence (P 5 0.019) (41) . Such results suggest that quantitative DWI should be further explored as an early biomarker for adaptive therapy.
Aside from tissue characterization, DWI is routinely incorporated in clinical protocols to facilitate lesion detection. The contrast in signal between bright tumor against the relatively dark normal tissue seen on diffusion-weighted images improves conspicuity. The extent of peritoneal carcinomatosis (Fig. 4) (42) and intrauterine tumor spread (38, 43) is more accurately assessed with DWI. In detection of lymphadenopathy, DWI when combined with conventional MR imaging has been shown to improve accuracy in some series (44, 45) and not in others (46) . Whole-body DWI (Fig. 5) is an emerging technique that allows for complete anatomic staging and detection of distant metastases (47) .
PET TRACERS IN DEVELOPMENT
Several PET tracers have shown promise in evaluating specific biologic features and clinical behavior of gynecologic cancers. One example is copper-labeled diacetyl-bis (N4-methylthiosemicarbazone) (copper-ATSM), which measures hypoxia. Tumor hypoxia is an important prognostic factor indicating decreased overall and disease-free survival in patients with cervical cancer (48, 49) . The gold standard for measuring hypoxia is oxygen electrodes. However, this method is subject to sampling error and is practically available only in readily accessible tumors. copper-ATSM is a neutral lipophilic molecule that diffuses from the blood to the surrounding cells. Once intracellular, it undergoes reduction and becomes trapped and accumulates avidly in hypoxic cells but washes out rapidly from normoxic cells without any change. ATSM has been labeled using several radioisotopes of copper; however, most commonly 60 Cu (23.4-min half-life, b1 5 81%), 62 Cu (9.7-min half-life, b1 5 97.5%), and 64 Cu (12.7-h half-life, b1 5 17%, b2 5 40%) have been used for clinical studies (50) . Several studies on patients with cervical cancer have shown that 60 Cu-ATSM uptake is predictive of survival; cause-specific and overall survival were significantly worse in patients with increased pretreatment copper-ATSM uptake within the primary tumor (51, 52) . In addition, tumor uptake of 18 F-FDG in these patients did not correlate with copper-ATSM uptake, as no significant difference was found in tumor 18 F-FDG uptake between patients with hypoxic (ATSM-avid) tumors and patients who had normoxic tumors. Thus, copper-ATSM has the potential to be used to select patients who are candidates for hypoxia-targeted therapy and to monitor hypoxia during such therapy.
Another tracer is 16a-18 F-fluoro-17b-estradiol ( 18 F-FES), an estrogen analog. 18 F-FES with 18 F-FDG has been used to image estrogen receptor expression and glucose metabolism, respectively, in endometrial lesions. Neither tracer alone could distinguish different types of endometrial lesions. However, high-risk carcinomas showed a significantly greater 18 F-FDG/ 18 F-FES ratio (3.6 6 2.1) than did low-risk carcinomas (1.3 6 0.5, P , 0.01) and hyperplastic lesions (0.3 6 0.1, P , 0.005). Thus, 18 F-FDG/ 18 F-FES ratio is a noninvasive tool that differentiates among 3 histologic types of endometrial lesions (53) .
The cell-proliferation radiotracer 39-deoxy-39-18 F-fluorothymidine ( 18 F-FLT) has been used in small clinical studies on patients with ovarian cancer. 18 F-FLT distributes rapidly in the extracellular fluid and is carried into the cytosol by nucleoside transporters, mainly by the equilibrative nucleoside transporter 1. Once inside the cell, 18 F-FLT is phosphorylated by thymidine kinase 1 and becomes trapped. Thus, the intracellular retention of 18 F-FLT is a measure of cellular thymidine kinase 1 activity, a principal enzyme in the salvage pathway of DNA synthesis, which is closely tied to cellular proliferation. 18 F-FLT uptake is higher in malignant lesions than in benign lesions (54) . However, it remains to be proven whether 18 F-FLT PET/CT is specific enough to distinguish between cancerous and noncancerous tissues. The role of 18 F-FLT PET/CT may be in assessing and predicting response to antitumor therapy, an area in which it has been shown to be superior to 18 F-FDG PET/CT.
PET/MR
PET/MR scanners acquire MR and PET data either simultaneously or sequentially. In the simultaneous acquisition device (mMR Biograph; Siemens), the PET and MR scanners are housed in a single gantry, allowing for concurrent imaging of the same body region (55) . In the sequential acquisition device (Ingenuity TF; Philips), 2 spatially separate PET and MR scanners are connected by a moving table that reduces changes in patient positioning between successive imaging events (56) . Both devices collect MR PET datasets in a single imaging session, allowing for fusion image analysis.
Although the immense technical hurdles of merging PET photodetectors and MR electromagnets have been largely addressed, PET/MR continues to face several technical challenges. Most important is how to correct for photon attenuation, as unlike with CT, MR data cannot be directly extrapolated for this purpose. Tissue decomposition using Dixon sequences back-calculates attenuation by measuring the relative amounts of fat and water. But this method cannot differentiate the signal void of air from that of bone, leading to systematic underestimation of its attenuating effects (57) . Possible solutions include atlas-based methods that retrospectively add missing tissue information and ultra-short echo time sequences that display tissues with very short T2* (e.g., bone) (58) . Despite the remaining technical challenges, PET/MR is emerging as an important clinical and investigative tool.
In gynecologic cancer patients, 18 F-FDG PET/MR protocols are intended to provide "one-stop shopping" for treatment planning. The examination assesses the locoregional extent of pelvic tumor and evaluates the entire body for nodal, peritoneal, and skeletal metastases. During the PET acquisition, whole-body Dixon images, the anatomically descriptive half-Fourier acquisition single-shot turbo spin-echo images, and fluid-sensitive inversion recovery images and DWI are coacquired in simultaneous PET/MR scanners. A dedicated pelvic MR imaging examination follows and includes dynamic intravenous gadolinium administration. Patient table times on the current scanners are long, approximately 1.0-1.5 h. Preliminary experience is encouraging. Lesions detected on PET or DWI can be precisely localized and characterized on the conventional MR sequences, thereby allowing for improved sensitivity without a loss of specificity. These include lymph node (Fig. 6 ) and bone and liver (Fig. 7) metastases. Although the resolution of MR is more limited than that of CT, it nevertheless can detect lesions below the resolution of PET, such as pulmonary nodules. Finally, the parameters standarized uptake value, apparent diffusion coefficient, and tumor volume can be measured in conjunction with the imaging information for more quantitative assessment.
CONCLUSION
Pelvic MR imaging and whole-body PET/CT fill complementary roles in the imaging assessment of gynecologic cancer. MR imaging diagnoses and defines tumor extent in the central pelvic soft tissues, and PET/CT evaluates for lymphadenopathy and extrapelvic metastases. Future improvements in scanner and postprocessing technology will likely expand the role of DCE MR imaging and DWI. PET tracers other than 18 F-FDG will offer evaluation of tumor phenotype noninvasively. Early experience with PET/MR imaging indicates that this technique will emerge as the mainstay of tracer development and imaging assessment in gynecologic cancer patients.
